NEUROCRINE BIOSCIENCES INC (NBIX)
About NEUROCRINE BIOSCIENCES INC
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $2.9B
- Net income
- $478.6M
- Total assets
- $4.6B
- Market cap
- $16.5B
- Gross margin
- 98.2%
- Operating margin
- 21.6%
- Net margin
- 16.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $2.9B
- Cost of revenue
- $52.1M
- Gross profit
- $2.8B
- Operating expenses
- $2.2B
- Operating income
- $619.1M
- Income tax
- $226.8M
- Net income
- $478.6M
- EPS (basic)
- $4.81
- EPS (diluted)
- $4.67
Balance sheet
- Total assets
- $4.6B
- Current assets
- $2.5B
- Total liabilities
- $1.4B
- Current liabilities
- $743.4M
- Shareholders’ equity
- $3.3B
Cash flow
- Operating cash flow
- $782.7M
- Investing cash flow
- -$264.4M
- Financing cash flow
- -$38.3M
- Net cash flow
- $480.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $16.5B
- P/E ratio
- 37.6
- EPS (diluted)
- $4.67
- Shares outstanding
- 93.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 23, 1996
Neurocrine Biosciences Inc (NBIX) Stock Price
- Profitable — net income of $478.6M in FY2025.
- Revenue grew 173% from FY2020 to FY2025.
- Gross margin of 98.2%, net margin 16.7%.
- Trading near its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 37.6.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review NEUROCRINE BIOSCIENCES INC.
Write a review
News about NEUROCRINE BIOSCIENCES INC
News & sentiment via Polygon.io
Neurocrine Biosciences Inc: frequently asked questions
Is Neurocrine Biosciences Inc an American company?
Yes — Neurocrine Biosciences Inc is an American company headquartered in San Diego, California. Its American-origin credentials have been independently reviewed and verified by americancompanies.com.
Where is Neurocrine Biosciences Inc headquartered?
Neurocrine Biosciences Inc is headquartered in San Diego, California, United States.
Is Neurocrine Biosciences Inc publicly traded?
Yes — Neurocrine Biosciences Inc is a publicly traded company. Its stock trades under the ticker symbol NBIX on the NASDAQ.
What does Neurocrine Biosciences Inc do?
Neurocrine Biosciences Inc is an American Pharmaceuticals company in the Health & Beauty sector.
